Selected article for: "high expression and recent study"

Author: Baum, Alina; García-Sastre, Adolfo
Title: Induction of type I interferon by RNA viruses: cellular receptors and their substrates
  • Document date: 2009_11_1
  • ID: 4c1nuv2p_39
    Snippet: LGP2 activity was confirmed to be specific to RLR signaling as its expression had no effect on TLR3 mediated IFN induction. (Rothenfusser et al. 2005; Yoneyama et al. 2005) . The role of LGP2 as a negative regulator of RIG-I signaling was confirmed in Lgp2 -/-mice infected with VSV (Venkataraman et al. 2007 ). The exact mechanism by which LGP2 interferes with RIG-I signaling has not been resolved. One possibility is that LGP2 simply sequesters ds.....
    Document: LGP2 activity was confirmed to be specific to RLR signaling as its expression had no effect on TLR3 mediated IFN induction. (Rothenfusser et al. 2005; Yoneyama et al. 2005) . The role of LGP2 as a negative regulator of RIG-I signaling was confirmed in Lgp2 -/-mice infected with VSV (Venkataraman et al. 2007 ). The exact mechanism by which LGP2 interferes with RIG-I signaling has not been resolved. One possibility is that LGP2 simply sequesters dsRNA from RIG-I. This potential mechanism is supported by LGP2's high binding affinity for poly(I:C) and synthetic dsRNA in vitro, and the high expression level of this protein following virus infection . Inhibition of RIG-I dimer formation has also been proposed as the possible mode of LGP2 inhibitory activity. This mechanism is supported by observed complex formation between LGP2 and RIG-I in infected cells and the structural similarity of LGP2 to RIG-I DCARD (Rothenfusser et al. 2005; Saito et al. 2007a ). Finally, observed association of LGP2 with MAVS in virus infected cells leads to a possible third mechanism for its activity. Komuro et al. demonstrated that LGP2 was able to compete with IKKe for MAVS binding, therefore inhibiting a downstream step in RIG-I mediated activation pathway (Komuro and Horvath 2006) . The RD of LGP2 when expressed alone is sufficient to inhibit RIG-I mediated signaling, but it is not as efficient as full length LGP2 (Murali et al. 2008) . Similarly to RIG-I RD, LGP2 RD is able to bind RNA and form dimers in vitro. The structure of LGP2 RD is very similar to that of the RIG-I RD (Pippig et al. 2009) . Surprisingly, binding assays with purified protein have revealed that LGP2 possesses no specificity to 5 0 ppp-RNA, and instead has very high affinity for any dsRNA, with the presence of phosphate groups appearing irrelevant. (Murali et al. 2008; Pippig et al. 2009 ). The RD of LGP2 has been shown to bind to the blunt-end of dsRNA and not to the phosphate backbone of the molecule (Li et al. 2009b ). Since RIG-I interacts with both 5 0 ppp-RNA and dsRNA, this finding still allows LGP2 to inhibit RIG-I signaling by dsRNA sequesteration or inhibition of RIG-I duplex formation. A recent study showed that LGP2 defective in RNA binding inhibited RIG-I to the same degree as wild-type LGP2; supporting the hypothesis that dsRNA sequesteration is not the primary mode of LGP2 mediated inhibition (Li et al. 2009b) .

    Search related documents:
    Co phrase search for related documents
    • activation pathway and binding affinity: 1
    • activation pathway and complex formation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activation pathway and dimer formation: 1
    • activation pathway and exact mechanism: 1
    • activation pathway and high affinity: 1, 2
    • activation pathway and high expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • activation pathway and hypothesis support: 1, 2, 3
    • activation pathway and IFN induction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity mechanism and binding affinity: 1, 2, 3
    • activity mechanism and complex formation: 1, 2, 3, 4
    • activity mechanism and dimer formation: 1
    • activity mechanism and duplex formation: 1
    • activity mechanism and exact mechanism: 1, 2, 3, 4, 5, 6
    • activity mechanism and IFN induction: 1, 2
    • bind assay and high expression: 1
    • bind assay and high expression level: 1
    • binding affinity and dimer formation: 1, 2
    • binding affinity and hypothesis support: 1, 2
    • binding affinity and IFN induction: 1, 2, 3